154 related articles for article (PubMed ID: 14552327)
1. COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer.
Piazuelo E; Jimenez P; Lanas A
Curr Pharm Des; 2003; 9(27):2267-80. PubMed ID: 14552327
[TBL] [Abstract][Full Text] [Related]
2. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study.
Buttar NS; Wang KK; Anderson MA; Dierkhising RA; Pacifico RJ; Krishnadath KK; Lutzke LS
J Natl Cancer Inst; 2002 Mar; 94(6):422-9. PubMed ID: 11904314
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
Souza RF; Shewmake K; Beer DG; Cryer B; Spechler SJ
Cancer Res; 2000 Oct; 60(20):5767-72. PubMed ID: 11059772
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure.
Shirvani VN; Ouatu-Lascar R; Kaur BS; Omary MB; Triadafilopoulos G
Gastroenterology; 2000 Mar; 118(3):487-96. PubMed ID: 10702199
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
Wilson KT; Fu S; Ramanujam KS; Meltzer SJ
Cancer Res; 1998 Jul; 58(14):2929-34. PubMed ID: 9679948
[TBL] [Abstract][Full Text] [Related]
6. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.
Kaur BS; Khamnehei N; Iravani M; Namburu SS; Lin O; Triadafilopoulos G
Gastroenterology; 2002 Jul; 123(1):60-7. PubMed ID: 12105834
[TBL] [Abstract][Full Text] [Related]
7. Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
Esquivias P; Morandeira A; Escartín A; Cebrián C; Santander S; Esteva F; García-González MA; Ortego J; Lanas A; Piazuelo E
World J Gastroenterol; 2012 Sep; 18(35):4866-74. PubMed ID: 23002358
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.
Buttar NS; Wang KK; Leontovich O; Westcott JY; Pacifico RJ; Anderson MA; Krishnadath KK; Lutzke LS; Burgart LJ
Gastroenterology; 2002 Apr; 122(4):1101-12. PubMed ID: 11910360
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus.
Gupta RA; DuBois RN
J Natl Cancer Inst; 2002 Mar; 94(6):406-7. PubMed ID: 11904306
[No Abstract] [Full Text] [Related]
11. Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression?
Fennerty MB
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S30-7. PubMed ID: 12478242
[TBL] [Abstract][Full Text] [Related]
12. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 expression in Barrett's esophagus.
Kandil HM; Tanner G; Smalley W; Halter S; Radhika A; Dubois RN
Dig Dis Sci; 2001 Apr; 46(4):785-9. PubMed ID: 11330414
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma.
Lagorce C; Paraf F; Vidaud D; Couvelard A; Wendum D; Martin A; Fléjou JF
Histopathology; 2003 May; 42(5):457-65. PubMed ID: 12713622
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects.
Majka J; Rembiasz K; Migaczewski M; Budzynski A; Ptak-Belowska A; Pabianczyk R; Urbanczyk K; Zub-Pokrowiecka A; Matlok M; Brzozowski T
J Physiol Pharmacol; 2010 Aug; 61(4):409-18. PubMed ID: 20814068
[TBL] [Abstract][Full Text] [Related]
16. [Medical treatment of Barrett's esophagus].
Kinoshita Y; Yuki T
Nihon Rinsho; 2005 Aug; 63(8):1449-53. PubMed ID: 16101238
[TBL] [Abstract][Full Text] [Related]
17. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Morris CD; Armstrong GR; Bigley G; Green H; Attwood SE
Am J Gastroenterol; 2001 Apr; 96(4):990-6. PubMed ID: 11316217
[TBL] [Abstract][Full Text] [Related]
19. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats.
Oyama K; Fujimura T; Ninomiya I; Miyashita T; Kinami S; Fushida S; Ohta T; Koichi M
Carcinogenesis; 2005 Mar; 26(3):565-70. PubMed ID: 15564290
[TBL] [Abstract][Full Text] [Related]
20. Acid increases proliferation via ERK and p38 MAPK-mediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells.
Souza RF; Shewmake K; Pearson S; Sarosi GA; Feagins LA; Ramirez RD; Terada LS; Spechler SJ
Am J Physiol Gastrointest Liver Physiol; 2004 Oct; 287(4):G743-8. PubMed ID: 15231484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
